EAGLE PHARMACT   FYE=12 (December)

Annual - Income Statement - Company Specific

Fiscal period	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Period End Date	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015	9/30/2014	9/30/2013
Product sales	214.54	65.02	72.32	73.99	70.39	45.33	40.65	12.97	4.63	5.31
Royalty income	98.27	106.52	110.48	112.90	142.93	153.88	99.04	8.26	10.71	8.36
Other income	3.81	--	5.00	9.00	--	37.50	49.80	45.00	3.77	--
Total Revenue	316.61	171.55	187.80	195.89	213.31	236.71	189.48	66.23	19.10	13.68
Cost of product sales	85.46	31.53	33.65	47.89	42.37	33.71	--	--	--	--
Cost of Revenue	--	--	--	--	--	23.47	34.32	15.65	11.71	7.38
Cost of royalty	9.48	10.65	11.82	13.01	19.54	--	20.99	--	--	--
Research and development	34.09	51.28	30.79	36.81	44.42	32.61	30.26	27.86	16.82	9.80
Selling, general and administrative	106.63	75.32	78.60	76.37	60.51	71.42	52.31	20.17	9.33	4.96
Restructuring charge	--	--	0.00	0.00	7.91	--	--	--	--	--
Legal settlement	--	--	--	--	--	(1.65)	--	--	--	--
Asset impairment charges	--	--	--	--	(2.70)	(7.24)	--	--	--	--
Gain on sale of asset	--	--	--	--	--	--	1.75	--	--	--
Changes in fair value of contingent consideration	--	--	--	--	0.76	7.38	--	--	--	--
Total Operating Expenses	235.65	168.78	154.85	174.08	176.70	162.72	136.13	63.67	37.86	22.13
Income (Loss) from operations	80.96	2.77	32.95	21.82	36.62	73.99	53.35	2.56	(18.76)	(8.46)
Interest expense	4.05	1.64	2.58	2.69	2.74	1.14	0.01	0.01	0.01	0.31
Net proceeds from arbitration	--	--	--	--	--	--	--	--	--	(4.05)
Interest income	0.27	0.56	0.56	2.17	0.16	0.09	0.08	0.03	0.03	0.00
Other income/(expense), net	(15.75)	(6.24)	(8.26)	0.70	--	--	--	--	0.04	0.00
Deferred financing costs	--	--	--	--	--	--	--	--	--	(0.10)
Amortization of debt discount	--	--	--	--	--	--	--	--	--	(1.09)
Change in value of warrant liability	--	--	--	--	--	--	--	--	(0.57)	(1.05)
Total other income/(expense), net	(19.53)	(7.32)	(10.28)	0.18	(2.58)	(1.05)	0.08	0.01	(0.52)	1.51
Income (loss) before income tax	61.43	(4.55)	22.68	22.00	34.04	72.95	53.43	2.57	(19.27)	(6.95)
Income tax (benefit) expenses	25.79	4.08	10.69	7.69	2.14	21.00	(28.03)	0.00	(1.30)	(0.90)
Net Income (loss)	--	--	--	14.31	--	--	81.45	2.57	(17.98)	(6.05)
Dividends on Series A, B, B-1 and C Convertible Preferred Stock	--	--	--	--	--	--	--	--	1.67	3.84
Net income (loss) attributable to common stockholders	35.64	(8.63)	11.99	14.31	31.90	51.94	81.45	2.57	(19.64)	(9.89)
Income (Loss) per share attributable to common stockholders Basic	2.76	(0.66)	0.89	1.04	2.16	3.44	5.24	0.17	(1.97)	(3.25)
Income (Loss) per share attributable to common stockholders Diluted	2.73	(0.66)	0.87	1.01	2.09	3.27	4.96	0.16	(1.97)	(3.25)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING BASIC	12.93	13.05	13.48	13.76	14.77	15.10	15.53	15.25	9.96	3.04
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING DILUTED	13.07	13.05	13.77	14.14	15.28	15.91	16.43	16.25	9.96	3.04